AccScience Publishing / ITPS / Volume 6 / Issue 1 / DOI: 10.36922/itps.348
Cite this article
58
Download
1049
Views
Journal Browser
Volume | Year
Issue
Search
News and Announcements
View All
RESEARCH ARTICLE

Cardiovascular Evaluation in Patients with Systemic Sclerosis in the Turkish Population

Tarik Kivrak1* Mehdi Karasu1 Ozkan Karaca1 Suleyman Serdar Koca2
Show Less
1 Department of Cardiology, Firat University, Elazig, Turkey
2 Department of Rheumatology, Firat University, Elazig, Turkey
INNOSC Theranostics and Pharmacological Sciences 2023, 6(1), 22–27; https://doi.org/10.36922/itps.348
Submitted: 31 January 2023 | Accepted: 21 March 2023 | Published: 5 April 2023
© 2023 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC-by the license) ( https://creativecommons.org/licenses/by-nc/4.0/ )
Abstract

Cardiac involvement in systemic sclerosis (SSc) can lead to high morbidity and mortality. Therefore, early diagnosis and treatment are required. The aim of this study was to investigate the clinical, laboratory, and echocardiographic features of SSc, evaluate the proportion of patients with cardiovascular disease, and compare them with other population-based studies in the Turkish population. This study included 150 patients who were previously diagnosed and treated in the rheumatology clinic. Their age, sex, clinical signs and symptoms, laboratory and echocardiography findings, and concomitant diseases were evaluated. The results showed that the disease duration was <1 year and, at most, 11 years, with only one patient having elevated pulmonary artery pressure. In addition, patients with SSc in our region had similar demographic, clinical, laboratory, and echocardiographic features with those in other countries. This study demonstrated that hypertension is positively correlated with disease duration and the incidence of pulmonary hypertension is very low in patients with SSc.

Keywords
Systemic sclerosis
Cardiovascular disease
Scleroderma
Pulmonary hypertension
Hypertension
Funding
None.
References
[1]

Nikpour, M.; Stevens, M.W.; Herrick, A.L.; Proudman, S.M. Epidemiology of Systemic Sclerosis. Best Pract. Res. Clin. Rheumatol., 2010, 24, 857–69.

[2]

Silman, A.J. Epidemiology of Scleroderma. Ann. Rheum. Dis., 1991, 50, 846–53.

[3]

Preliminary Criteria for the Classification of Systemic Sclerosis (Scleroderma). Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum., 1980, 23, 581–90.

[4]

Van den Hoogen, F.; Khanna, D.; Fransen, J.; Johnson, S.R.; Baron, M.; Tyndall, A.; Matucci-Cerinic, M.; Naden, R.P.; Medsger, T.A. Jr.; Carreira, P.E.; Riemekasten, G.; Clements, P.J.; Denton, C.P.; Distler, O.; Allanore, Y.; Furst, D.E.; Gabrielli, A.; Mayes, M.D.; van Laar, J.M.; Seibold, J.R.; Czirjak, L.; Steen, V.D.; Inanc, M.; Kowal-Bielecka, O.; Müller-Ladner, U.; Valentini, G.; Veale, D.J.; Vonk, M.C.; Walker, U.A.; Chung, L.; Collier, D.H.; Csuka, M.E.; Fessler, B.J.; Guiducci, S.; Herrick, A.; Hsu, V.M.; Jimenez, S.; Kahaleh, B.; Merkel, P.A.; Sierakowski, S.; Silver, R.M.; Simms, R.W.; Varga, J.; Pope, J.E. 2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/ European League Against Rheumatism Collaborative İnitiative. Ann. Rheum. Dis., 2013, 72, 1747–55. 

[5]

Semenov, V.; Kuryata, O.; Lysunets, T. Clinical Pattern of Systemic Sclerosis in Central Ukraine. Association Between Clinical Manifestations of Systemic Sclerosis and Hypertension. Reumatologia, 2018, 56(1), 24–30.

[6]

Minier, T.; Guiducci, S.; Bellando-Randone, S.; Bruni, C.; Lepri, G.; Czirják, L.; Distler, O.; Walker, U.A.; Fransen, J.; Allanore, Y.; Denton, C.; Cutolo, M.; Tyndall, A.; Müller-Ladner, U.; Matucci- Cerinic, M.; EUSTAR Co-Workers.; EUSTAR Co-Workers. Preliminary Analysis of the Very Early Diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR Multicentre Study: Evidence for Puffy Fingers as a Pivotal Sign for Suspicion of Systemic Sclerosis. Ann. Rheum. Dis., 2014, 73, 2087–93.

[7]

Kuryata, O.V.; Lysunets. T.K.; Semenov, V.V. Risk and Predictors of Development of Arterial Hypertension in Patients with Systemic Sclerosis. Arterial Hypertens., 2017, 53, 17–22.

[8]

Underwood, J.C.; Cross, S.S. Osteoarticular and Connective Tissues. In: Hughes, D.E.; editor. General and Systematic Pathology. 5th ed. Churchill Livingstone, Edinburgh, 2009. p710–474.

[9]

Agca, R.; Heslinga, S.C.; Rollefstad, S.; Heslinga, M.; McInnes, I.B.; Peters, M.J.L.; Kvien, T.K.; Dougados, M.; Radner, H.; Atzeni, F.; Primdahl, J.; Södergren, A.; Jonsson, S.W.; van Rompay, J.; Zabalan, C.; Pedersen, T.R.; Jacobsson, L.; de Vlam, K.; Gonzalez-Gay, M.A.; Semb, A.G.; Kitas, G.D.; Smulders, Y.M.; Szekanecz, Z.; Sattar, N.; Symmons, D.P.M.; Nurmohamed, M.T. EULAR Recommendations for Cardiovascular Disease Risk Management in Patients with Rheumatoid Arthritis and Other Forms of İnflammatory Joint Disorders: 2015/2016 Update. Ann. Rheum. Dis., 2017, 76, 17–28.

[10]

Argula, R.G.; Harley. R.A.; Silver, R.M. Is Systemic Sclerosis- Related Pulmonary Arterial Hypertension a Distinct Phenotype? A Lung Morphometric Analysis of Systemic Sclerosis-Associated vs. İdiopathic Pulmonary Arterial Hypertension. J. Scleroderma Relat. Disord., 2017, 2(suppl 1), s1–20.

[11]

Condliffe, R.; Howard, L.S. Connective tissue disease-associated pulmonary arterial hypertension. F1000 Prime Cum, 2015, 7, 6.

[12]

Condliffe, R.; Kiely, D.G.; Peacock, A.J.; Corris, P.A.; Gibbs, J.S.; Vrapi, F.; et al. Connective tissue disease-associated pulmonary arter- ial hypertension in the modern treatment era. Am. J. Respir. Crit. Care Med., 2009, 179, 151–7. 

[13]

Al-Mutari, N. Skin Diseases Seen in Diabetes Mellitus. Bull. Kuwait Inst. Med. Spec., 2006, 5, 30–9.

[14]

Pavlović, M.D.; Milenković, T.; Dinić, M.; Misović, M.; Daković, D.; Todorović, S.; Daković, Z.; Zecevi, R.D.; Doder, R. The Prevalence of Cutaneous Manifestations in Young Patients with Type 1 Diabetes. Diabetes Care, 2007, 30(8), 1964–7.

[15]

Gruson, L.M.; Franks, A. Jr. Scleredema and Diabetic Sclerodactyly. Dermatol. Online J., 2005, 11(4), 3.

[16]

Medsger, TA. Jr.; Masi, A.T.; Rodnan, G.P.; Benedek, T.G.; Robinson, H. Survival with Systemic Sclerosis (Scleroderma). A Life-Table Analysis of Clinical and Demographic Factors in 309 Patients. Ann. Intern. Med., 1971, 75(3), 369–76.

[17]

Boueiz, A.; Mathai, S.C.; Hummers, L.K.; Hassoun, P.M. Cardiac Complications of Systemic Sclerosis: Recent Progress in Diagnosis. Curr. Opin. Rheumatol., 2010, 22(6), 696–703.

[18]

Roman, M.J.; Salmon, J.E. Cardiovascular Manifestations of Rheumatologic Diseases. Circulation, 2007, 116(20), 2346–55. 

[19]

Denton, C.P.; Cables, J.B.; Phillips, G.D.; Wells, A.U.; Black, C.M.; Bois, R.M. Comparison of Doppler Echocardiography and Right Heart Catheterization to Assess Pulmonary Hypertension in Systemic Sclerosis. Br. J. Rheumatol., 1997, 36(2), 239–43.

[20]

Hachulla, E.; Gressin, V.; Guillevin, L.; Carpentier, P.; Diot, E.; Sibilia, J.; Kahan, A.; Cabane, J.; Francès, C.; Launay, D.; Humbert, M. Early Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis: A French Nationwide Prospective Multicenter Study. Arthritis Rheum., 2005, 52(12), 3792–800.

[21]

Mukerjee, D.; St George, D.; Coleiro, B.; Knight, C.; Denton, C.P.; Davar, J.; Black, C.M.; Coghlan, J.G. Prevalence and Outcome in Systemic Sclerosis Associated Pulmonary Arterial Hypertension: Applycation a Registry Approach. Ann. Rheum. Dis., 2003, 62(11), 1088–93. 

[22]

Allanore, Y.; Meune, C.; Vonk, M.C.; Airo, P.; Hachulla, E.; Caramaschi, P.; Riemekasten, G.; Cozzi, F.; Beretta, L.; Derk, C.T.; Komócsi, A.; Farge, D.; Balbir, A.; Riccieri, V.; Distler, O.; Chialà, A.; Del Papa, N.; Simic, K.P.; Ghio, M.; Stamenkovic, B.; Rednic, S.; Host, N.; Pellerito, R.; Zegers, E.; Kahan, A.; Walker, U.A.; Matucci- Cerinic, M.; EUSTAR Co-Authors. Prevalence and Factors Associated with Left Ventricular Dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) Database of Patients with Systemic Sclerosis. Ann. Rheum. Dis., 2010, 69(1), 218–21. 

[23]

Meune, C.; Avouac, J.; Wahbi, K.; Cabanes, L.; Wipff, J.; Mouthon, L.; Guillevin, L.; Kahan, A.; Allanore, Y. Cardiac İnvolvement in Systemic Sclerosis Assessed by Tissue-Doppler Echocardiography During Routine Care: A Controlled Study of 100 Consecutive Patients. Arthritis Rheum., 2008, 58(6), 1803–9.

[24]

De Groote, P.; Gressin, V.; Hachulla, E.; Carpentier, P.; Guillevin, L.; Kahan, A.; Cabane, J.; Francès, C.; Lamblin, N.; Diot, E.; Patat, F.; Sibilia, J.; Petit, H.; Cracowski, J.L.; Clerson, P.; Humbert, M.; ItinerAIR-Scleroderma Investigators. Evaluation of Cardiac Abnormalities by Doppler Echocardiography in a Large Nationwide Multicentric Cohort of Patients with Systemic Sclerosis. Ann. Rheum. Dis., 2008, 67(1), 31–6.

[25]

Maione, S.; Cuomo, G.; Giunta, A.; de Horatio, L.T.; La Montagna, G.; Manguso, F.; Alagia, I.; Valentini, G. Echocardiographic Alterations in Systemic Sclerosis: A Longitudinal Study. Semin. Arthritis Rheum., 2005, 34(5), 721–7.

[26]

Candell-Riera, J.; Armadans-Gil, L.; Simeón, C.P.; Castell-Conesa, J.; Fonollosa-Pla, V.; García-del-Castillo, H.; Vaqué-Rafart, J.; Vilardell, M.; Soler-Soler, J. Comprehensive Noninvasive Assessment of Cardiac İnvolvement in Limited Systemic Sclerosis. Arthritis Rheum., 1996, 39(7), 1138–45.

Conflict of interest
The authors declare no conflicts of interests.
Share
Back to top
INNOSC Theranostics and Pharmacological Sciences, Electronic ISSN: 2705-0823 Published by AccScience Publishing